Abstract:Yunbin Yang, Jinou Chen, Liangli Liu, Ling Li, Rui Yang, Kunyun Lu, Yubing Qiu, Xing Yang, Lin Xu Division of Tuberculosis Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, People's Republic of China Correspondence: Lin Xu, Email Objective: Treating and managing rifampicin resistant tuberculosis (RR-TB) patients in Yunnan, China, are major challenges. This study aims to evaluate the risk of poor treatment outcomes in RR-TB patients, allowing clinical doctors to proactively target patients who would benefit from enhanced patient management. Methods: Four RR-TB care facilities in different regions of Yunnan province as the data collection points were selected. A total of 524 RR-TB patients were included in this study and randomly assigned into a training set (n=366) and a validation set (n=158). In the training set, four significant factors were screened by using a random forest model and a Lasso regression model, and then included in a logistic regression model to construct a nomogram for internal validation. Results: The successful treatment rate of RR-TB patients in training set was 42.6% (156/366), and the main poor treatment outcomes were loss to follow-up (66.7%) and death (18.1%). Low hemoglobin (HGB) (OR=0.977, 95% CI: 0.964– 0.989), long-regime (OR=2.784, 95% CI: 1.634– 4.842), poor culture results at the end of the 6th month (CR6TM) (OR=11.193, 95% CI: 6.507– 20.028), pre-extensively drug-resistant tuberculosis (pre-XDR) (OR=3.736, 95% CI: 1.294– 12.034) were risk factors for poor treatment outcomes in RR-TB patients. The Area Under Curve (AUC) of this model was 0.829 (95% CI: 0.787– 0.870), and there was good consistency between the predicted probability and the actual probability. The DCA curve showed that when the threshold probability was 20– 98%, the use of nomogram to predict the net benefit of poor treatment outcomes risk in RR-TB patients was higher. Conclusion: We combined multiple models to develop a nomogram for predicting poor treatment outcomes in RR-TB patients. This would help clinical doctors identify high-risk populations and enable them to proactively target RR-TB patients who will benefit from strengthened patient management. Keywords: drug resistance tuberculosis, poor treatment outcomes, prediction, model, nomogram Rifampicin resistant tuberculosis (RR-TB) is characterized by challenging diagnosis, long treatment duration, high treatment costs, more adverse reactions, and a high loss rate. 1,2 According to the World Health Organization (WHO), in China, there were approximately 30,000 RR-TB patients, accounting for 7.3% of the global total. In 2020, the successful treatment rate of RR-TB patients undergoing treatment was only 51%. 3 Ethiopian studies showed that 38–92% of TB patients reported income loss and 26–76% of TB patients lost their jobs due to unfavorable outcomes of RR-TB, further worsening the financial problem. 4 Yunnan, situated on China's southwestern border, is an economically underdeveloped province comprising 16 prefectures and 129 counties. The successful treatment rate for RR-TB patients in Yunnan was only about 50%~60%, with nearly 40%~50% of RR-TB patients experiencing poor treatment outcomes for various reasons, resulting in the continued spread of drug-resistant bacteria throughout the community. 5,6 Therefore, it is essential to analyze the factors associated with poor treatment outcome in RR-TB patients to prioritize intervention to improve outcomes among RR-TB patients with elevated risks. Many risk factors associated with unsuccessful treat ment outcomes of RR-TB had been reported, including older age, baseline alcohol use, cavitary disease, culture-positive at baseline, relapsed TB, treatment non-compliance, previous TB treatment, longer treatment duration and history of second-line drug resistance. 7–9 The clinical characteristic data that clinicians pay more attention to were less included in previous studies. At the same time, the clinical data were collected from only one facility would inevitably lead to the unrepresentativeness and unrepeatability of the analysis results. In addition, when many variables with highly linear correlation were collected, only using logistic regression model was easy to cause equation over fitting, and the included variables needed to be controlled and limited. Considering the above factors, this study included the multi-dimensional data of multiple RR-TB care facilities in Yunnan, and applied multiple statistical models to screen and control variable for the construction of influencing factor models, aiming to evaluate the risk of poor treatment outcomes in RR-TB patients in Yunnan, allowing clinical doctors to proactively target patients who would -Abstract Truncated-

Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Treatment Quality and Outcome for Multidrug-Resistant Tuberculosis Patients in Four Regions of China: a Cohort Study.

Diagnosis and Treatment Pathway of MDR/RR-TB in Taizhou, Zhejiang Province, China

Treatment Outcomes of Multidrug-Resistant Tuberculosis Patients Receiving Ambulatory Treatment in Shenzhen, China: a Retrospective Cohort Study.

Factors Contributing to the High Prevalence of Multidrug-Resistant Tuberculosis: a Study from China

Treatment Outcomes and Associated Influencing Factors Among Patients with Rifampicin-Resistant Tuberculosis: A Multicenter, Retrospective, Cohort Study in China

Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China

Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

Changing trend analysis on early detection of rifampicin resistant tuberculosis patients in southwestern area of China, 2016–2020

Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study

Factors Associated with Non-Adherence to Treatment Among Migrants with MDR-TB in Wuhan, China: A Cross-Sectional Study

Applying a Combined Model to Evaluate the Risk of Poor Treatment Outcomes in Rifampicin Resistant Tuberculosis Patients: A Multicenter Retrospective Study

Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment

Transmission of multidrug-resistant tuberculosis in Jiangxi, China, and associated risk factors

Access to Bacteriologic-Based Diagnosis in Smear Positive Retreatment Tuberculosis Patients in Rural China: A Cross-Sectional Study in Three Geographic Varied Provinces.

Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: an Ambispective Cohort Study

Predictors and Trends of MDR/RR-TB in Shenzhen China: A Retrospective 2012-2020 Period Analysis

Treatment outcomes of the standardized regimens for patients with multidrug-resistant pulmonary tuberculosis in Wenzhou during 2013 to 2015

Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study

Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial